Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 29-36

  McIntyre, Dominick J O ^a   Howe, Franklyn A ^b   Ladroue, Christophe ^c   Lofts, Fiona ^b   Stubbs, Marion ^a   Griffiths, John R ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

19F; 5FU; Colorectal; Liver; Magnetic resonance spectroscopy; Metastasis

Indexed keywords

DRUG METABOLITE; FLUORONUCLEOTIDE; FLUOROURACIL; NUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; FEMALE; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARBON DIOXIDE; COLON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OXYGEN; RECTUM; TUMOR BURDEN;

EID: 79959593668     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1438-2     Document Type: Article

References (26)

1. Segal NH, Saltz LB (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60:207-219
2. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343:1184-1187 (Pubitemid 24147552)
3. Findlay MPN, Raynaud F, Cunningham D, Iveson A, Collins DJ, Leach MO (1996) Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-a. Ann Oncol 7:47-53
4. Wolf W, Presant CA, Servis KL, El-Tahtawy A, Albright MJ, Barker PB, Ring R III, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blayney D, Shani J (1990) Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proceedings of the National Academy of Sciences 87:492-496
5. Wolf W, Waluch V, Presant CA (1998) Non-invasive F-19-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 11:380-387 (Pubitemid 28547373)
6. Wolf W, Presant CA, Waluch V (2000) 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 41:55-74
7. Kamm YJL, Heerschap A, van den Bergh EJ, Wagener DJT (2004) 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anti-Cancer Drugs 15:229-233
8. van Laarhoven HWM, Klomp DWJ, Rijpkema M, Kamm YLM, Wagener DJT, Barentsz JO, Punt CJA, Heerschap A (2007) Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 20:128-140
9. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR (1984) 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer 50:113-117 (Pubitemid 14092653)
10. McSheehy PMJ, Robinson SP, Ojugo ASE, Aboagye EO, Cannell MB, Leach MO, Judson IR, Griffiths JR (1998) Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res 58:1185-1194 (Pubitemid 28183207)
11. Sijens PE, Huang Y, Baldwin NJ, Ng TC (1991) 19F Magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine rif-1 tumors and liver. Cancer Res 51:1384-1390
12. McSheehy PM, Prior MJ, Griffiths JR (1989) Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer 60:303-309 (Pubitemid 19227396)
13. Doi Y, Shimmura T, Kuribayashi H, Tanaka Y, Kanazawa Y (2009) Quantitative 19F imaging of nmol-level F-nucleotides/-sides from 5-FU with T2 mapping in mice at 9.4T. Magn Reson Med 62:1129-1139
14. Findlay MP, Leach MO (1994) In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anti-Cancer Drugs 5:260-280
15. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA 12:141-152 (Pubitemid 32510133)
16. Vanhamme L, van den Boogaart A, Van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129:35-43 (Pubitemid 127454051)
17. Kamm YJL, Heerschap A, Wagener DJT (2000) Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma. Eur J Cancer 36:1180-1186 (Pubitemid 30330917)
18. Griffiths JR, McIntyre DJO, Howe FA, McSheehy PMJ, Ojugo ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F, Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M (2001) Issues of normal tissue toxicity in patient and animal studies - Effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncol 40:609-614 (Pubitemid 32912439)
19. Ojugo ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths JR (1998) Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer 77:873-879 (Pubitemid 28101772)
20. Guerquin-Kern J-L, Leteurtre F, Croisy A, Lhoste J-M (1991) pH Dependence of 5-fluorouracil uptake observed by in vivo 31p and 19f nuclear magnetic resonance spectroscopy. Cancer Res 51:5770-5773
21. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR (1999) Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging 17:1307-1318 (Pubitemid 29534104)
22. Honess DJ, Bleehen NM (1995) Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer 71:1175-1180
23. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM (2006) Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 12:3115-3123 (Pubitemid 43837359)
24. van Laarhoven HWM, Gambarota G, Lok J, Lammens M, Kamm YLM, Wagener T, Punt CJA, van der Kogelz AJ, Heerschap A (2006) Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. Neoplasia 8:477-487 (Pubitemid 44035332)
25. van Laarhoven HWM, Klomp DWJ, Kamm YJL, Punt CJA, Heerschap A (2003) In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 tesla field strength. Cancer Res 63:7609-7612
26. Klomp DWJ, van Laarhoven HWM, Scheenen T, Kamm YJL, Heerschap A (2007) Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 20:485-492 (Pubitemid 47272368)